Ironwood Pharmaceuticals, Inc. (IRWD) Market Cap & Valuation Ratios
Ironwood Pharmaceuticals, Inc. (IRWD) has a market cap of $571.7M, a trailing P/E of 4.5 and a price-to-sales ratio of 1.5, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 571.7M
- P/E TTM
- 4.5
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Peers
drug manufacturers - specialty & generic · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| IRWD | 0.6 | 4.5 | 1.3 | 2.1 | — | +26% | 60% | — |
| CRON | 1.2 | 16.9 | 2.4 | 36.9 | 4.0% | +37% | -1% | -0.5% |
| AMPH | 1.1 | 14.9 | 1.9 | 8.1 | 14.3% | +1% | 16% | 8% |
| HROW | 1.1 | — | 4.6 | — | 0.5% | +21% | -1.0% | -2% |
| COLL | 0.7 | — | 2.1 | 4.4 | — | +14% | 19% | 9% |
| AQST | 0.5 | — | 8.4 | — | -9.2% | +23% | -98% | — |
| EOLS | 0.5 | — | 1.8 | — | -4.7% | +14% | -6% | -26% |
| TLRY | 0.4 | — | 0.4 | — | — | +16% | -9% | -6% |
| EBS | 0.3 | — | 1.0 | 26.8 | — | -10% | -9% | -8% |
| ANIK | 0.3 | — | 2.1 | 496.5 | 0.2% | +5% | -4% | -5% |
| CGC | 0.3 | — | — | — | — | +7% | -55% | -26% |
| Median of these 10 | 15.9 | 2.1 | 26.8 | 0.3% | +14% | -5% | -5% |
P/E 4.5 vs. a peer median of 15.9; EV/Sales 1.3 vs. 2.1. IRWD's own P/E sits at the 32nd percentile of its history.
Growth vs. price
each dot a company · hover or tap for valuesHROW and COLL and AQST and EOLS and TLRY and EBS and ANIK and CGC have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
Ironwood Pharmaceuticals, Inc. — questions
- What is Ironwood Pharmaceuticals, Inc.'s market cap?
- $571.7M.
- What is Ironwood Pharmaceuticals, Inc.'s P/E ratio?
- 4.5 on trailing twelve-month earnings to 2026-06-30.
- What is Ironwood Pharmaceuticals, Inc.'s price-to-sales ratio?
- 1.5.
Every figure on this page comes from Ironwood Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.